Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CB-011 |
Synonyms | |
Therapy Description |
CB-011 are allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting BCMA (TNFRSF17), which also has disruption of TRAC, deletion of B2M, and insertion of a B2M-HLA-E fusion protein transgene to reduce rejection, potentially leading to enhanced CAR-T cell persistence and antitumor activity (Cancer Res (2022) 82 (12_Supplement): LB009). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CB-011 | CB 011|CB011 | CB-011 are allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting BCMA (TNFRSF17), which also has disruption of TRAC, deletion of B2M, and insertion of a B2M-HLA-E fusion protein transgene to reduce rejection, potentially leading to enhanced CAR-T cell persistence and antitumor activity (Cancer Res (2022) 82 (12_Supplement): LB009). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05722418 | Phase I | CB-011 | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (CaMMouflage) | Recruiting | USA | 0 |